ADMIRAL trial enrolled 371 patients with relapsed/refractory FLT3-mutated (ITD or TKD) AML, randomly assigned (2:1) to receive either gilteritinib (120 mg per day) or salvage chemotherapy. Here, FLT3 is linked to acute myeloid leukemia.